Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > CHECK out ONC.TO Cancer breakthrough?

<< Previous

Bullboard Posts

Next >>

Comment by Goaweighon Feb 17, 2021 11:34am

138 Views

Post# 32584713

RE:RE:RE:RE:RE:CHECK out ONC.TO Cancer breakthrough?

The mark of a good CEO is to know what you don't know and hire people who do so he's hired Stern IR, a US IR firm with a large US Biotech client list.
I suspect they have a listing strategy that's very well thought out and may include a sponsorship and/or a raise but whatever, they certainly have a plan to drive US investor awareness.
Could get interesting.. LOL

crow27 wrote: I believe Dan wants to build a solid base/foundation for the stock before he moves it to the Nasdaq.
Maybe announce another deal? He has a plan and for some reason he feels this is the way to do it. I'm in line and agree with his plan.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario